

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Protocol for the Study Investigating Markers in Pleural Effusion (SIMPLE study): A prospective and double blinded diagnostic study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-027287
Article Type:	Protocol
Date Submitted by the Author:	21-Oct-2018
Complete List of Authors:	Han, Yan-Qiu; the Affiliated Hospital of Inner Mongolia Medical University, Department of Laboratory Medicine Yan, Li; the Affiliated Hospital of Inner Mongolia Medical University, Department of Respiratory and Critical Care Medicine Li, Peng; the Affiliated Hospital of Inner Mongolia Medical University, Department of Laboratory Medicine Zhang, Lei; the Affiliated Hospital of Inner Mongolia Medical University, Department of Laboratory Medicine Ouyang, Pei-Heng; the Affiliated Hospital of Inner Mongolia Medical University, Department of Laboratory Medicine Hu, Zhi-De; the Affiliated Hospital of Inner Mongolia Medical University, Department of Laboratory Medicine
Keywords:	Diagnostic accuracy test, Biomarkers, Pleural effusion

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 **Protocol for a Study Investigating Markers in PLeural Effusion (SIMPLE study): A prospective**  
5  
6 **and double-blind diagnostic study**  
7  
8

9 Yan-Qiu Han<sup>1</sup>, Li Yan<sup>2</sup>, Peng Li<sup>1</sup>, Lei Zhang<sup>1</sup>, Pei-Heng Ouyang<sup>1</sup>, Zhi-De Hu<sup>1,\*</sup>  
10  
11

12  
13 <sup>1</sup> Department of Laboratory Medicine, the Affiliated Hospital of Inner Mongolia Medical University,  
14 Hohhot, China.  
15

16  
17 <sup>2</sup> Department of Respiratory and Critical Care Medicine, the Affiliated Hospital of Inner Mongolia  
18 Medical University, Hohhot, China.  
19  
20

21  
22  
23 **Correspondence to:** Dr Zhi-De Hu; [hzdj81@163.com](mailto:hzdj81@163.com)  
24  
25

26  
27 Word count: 2353  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

**Introduction:** Serum and pleural effusion (PE) markers, due to their advantages of low cost, objective result and short turn-around time, are valuable for exploring the etiologies of PE. The diagnostic accuracy of potential markers needs to be rigorously evaluated before their widespread application in clinical practice. Here, we plan to perform a Study Investigating Markers in Pleural Effusion (SIMPLE study).

**Methods and analysis:** This is a prospective and double-blind study will be performed in the Affiliated Hospital of Inner Mongolia Medical University, China. Adult patients with PE of unknown causes and admitted to our institution between September 2018 and July 2021, will be enrolled. PE and matched serum specimens will be collected and stored at  $-80^{\circ}\text{C}$  for research aims. Diagnosis of the included subjects will be proved with imaging, microbiology, cytology and biopsy. The results of investigated markers will be unknown to the clinicians who will make diagnosis and the clinical diagnoses will be unknown to the laboratory technicians who will determine markers. The diagnostic accuracy of investigated markers will be assessed using receiver operating characteristics (ROC) curve analysis, multivariable logistic regression model, net reclassification index (NRI) and integrated discriminatory index (IDI).

**Ethics:** This study has been approved by the Ethic Committee of the Affiliated Hospital of Inner Mongolia Medical University (NO: 2018011).

**Study registration:** This study has been registered with the Chinese Clinical Trial Registry platform, with a registration number of ChiCTR1800017449.

**Keywords:** Biomarkers; Pleural effusion; Diagnostic accuracy test

**Strengths and limitations of this study**

- A prospective designed study evaluating the diagnostic value of pleural effusion and serum biomarkers in subjects with pleural effusion.
- Double-blinded: the clinician madding diagnosis will be masked to the results of biomarker and the laboratory technician determining biomarker will be masked to the clinical picture of subjects.
- Multiple biomarkers for various target diseases will be studied.
- Multiple etiologies will be considered when making diagnosis.

## Introduction

Pleural effusion (PE) is a frequent problem in clinical practice and can be caused by various disorders such as heart failure (HF), malignant diseases, tuberculosis and pneumonia [1,2]. A correct and timely diagnosis is the prerequisite for PE management. Currently, several tools are available for exploring the etiologies of PE, including thoracoscopy, imaging, cytology and bacterial culture [3,4]. Of these tools, thoracoscopy is the most widely-used one and has good diagnostic performance for various disorders. Nevertheless, a previous study indicated that approximately 7% of patients remain undiagnosed after thoracoscopy [2]. Besides, thoracoscopy is an invasive tool and operation-related complications are really a problem. Although some non-invasive diagnostic tools, such as microbiological and cytological examinations, have high specificity for given diseases, their diagnostic sensitivities are unsatisfactory [5–8]. Besides, the diagnostic accuracy of these tools, as well as imaging approaches and thoracoscopy, depends largely on the experience of operator and pathologist [9]. Bacterial culture has high diagnostic specificity for infectious diseases including pneumonia and tuberculosis; however, the long turnaround time (TAT) limits its application in clinical setting.

By contrast, serum and PE biochemistry analyses have some advantages in exploring etiologies, including low cost, short TAT, easy to standardization and less operator or observer variations. Indeed, some markers in PE or serum have shown extremely high diagnostic accuracy in patients with PE. For instance, PE levels of interleukin-27 (IL-27) [10], interferon-gamma [11] and adenosine deaminase (ADA) [12] for tuberculous PE, and N-terminal pro-brain natriuretic peptide (NT-proBNP) for HF [13,14]. However, for malignant diseases and infectious diseases, the diagnostic accuracy of available biomarkers such as tumor markers [14–16], procalcitonin (PCT) [17] and C-reactive protein (CRP) [18] is unsatisfactory. Therefore, further works are needed to identify novel markers and rigorously evaluate their diagnostic accuracy.

To better understand the diagnostic value of PE and serum markers in patients with PE, we plan to perform a prospective, double-blind diagnostic study, named A Study Investigating Markers in Pleural Effusion (SIMPLE study).

## Method

### Trial registration, foundation and ethic approval

This study has been approved by the Ethic Committee of the Affiliated Hospital of Inner Mongolia Medical University (NO: 2018011). All subjects, or their guardians, will be given a full informed consent before taking part. The study has been registered with the Chinese Clinical Trial Registry platform (<http://www.chictr.org.cn/index.aspx>. Registration number: ChiCTR1800017449). Currently, this study is not supported by any grant; however, it may be supported by some grants from the Affiliated Hospital of Inner Mongolia Medical University or government in future. The funders will not be involved in study design, sample collection, data analysis, manuscript preparation and decision to publish.

### Subject enrollment and specimen collection

Subjects with PE and unknown etiology are eligible for enrollment. The presence of PE will be proved by CT or ultrasound. The exclusion criteria are: (i) age less than 18 years; (ii) with a history of diseases that can cause PE during the last three months; (iii) pregnancy; (iv) refused to sign informed consent; (v) with comorbidities that can prevent PE collection.

PE specimen collection will be initiated after the informed consent process. Approximately 5-10 milliliters PE specimen will be collected in a tube that does not contain any anticoagulant. The specimen will be sent to laboratory within 2 hours and centrifuged at 1200g for 10 minutes. The supernatants of PE specimen will be transferred to 10 Eppendorf tubes (510  $\mu$ l each tube) and immediately frozen at  $-80^{\circ}\text{C}$  for later using. A matched serum sample, which is sent to the laboratory 24 hours before or after PE specimen collection, will be also collected and frozen at  $-80^{\circ}\text{C}$  if available.

All subjects will be enrolled by a respirologist (L Yan). The subjects will be not consecutively enrolled because they may: (i) refuse to sign the informed consent; (ii) be admitted at weekend when Dr. Yan is not on duty; (iii) not be admitted to the Department of Respiratory and Critical Care Medicine of our institution.

The laboratory technician who determines the concentration of investigated markers will be

blinded to clinical picture of the subjects.

### Sample size estimation

As this is not a hypothesis-driven research and none target disease or biomarker is proposed, we did not estimate the sample size before subjects' enrollment. The study execute time lasts from September 2018 to July 2021. It is estimated that 200 to 500 subjects will be enrolled.

### Final diagnosis

This is an observational study that does not affect the further management of the enrolled subjects. The clinicians decided the further diagnostic or treatment procedures independent of this study. The etiologies of PE are various and the diagnostic criteria for the major diseases are listed in **Table 1**. The final diagnosis will be made by a researcher (L Yan) and the results of investigated biomarkers is unknown when making diagnosis.

**Table 1** Diagnostic criteria for major diseases related to PE

Etiology	Diagnostic criteria
Tuberculosis	Identification of <i>Mycobacterium tuberculosis</i> in the sputum, pleural fluid, or pleural biopsy specimens [19], either by microscopy or cultures. In some cases with adequate clinical context, the diagnosis can be made with granuloma in the parietal pleura, good response to anti-tuberculosis treatment, elevated level of PE adenosine deaminase or positive nucleic acid amplification tests (NAATs) [19–21].
Heart failure	Typical clinical picture of heart failure, including the Framingham score, medical history, the response to diuretic therapy, chest radiography, the echocardiographic evidence of left ventricular systolic dysfunction [13,22–24].
Malignant diseases	Identification of cancer cells in PE, sputum or bronchoalveolar lavage fluid by cytological examination, ultrasound or thoracoscopy-guided



	pleural biopsy [3,23].
Pneumonia	Typical clinical and radiological evidences of pneumonia, or a positive bacterial culture in PE, or good response to antibiotic therapy [3,23].
Pulmonary embolism	Computed tomographic pulmonary angiography (CTPA) [25].

Given that approximately 30% of PEs have more than one etiology and the most common secondary cause is HF [26,27]. Therefore, all patients will be evaluated whether they have HF. For some subjects, the possible etiologies can change during their admission (i.e. HF secondary to pneumonia), only the diagnosis at the time of specimen collection will be used. It is estimated that some subjects' diagnosis remains unknown after discharging. This may be due to the fact that some subjects will refuse to receive invasive approaches, such as thoracoscopy. The number of these subjects will be recorded and reported. The subjects die during hospital will be excluded into analysis.

### Patient and public involvement

**Figure 1** is a flowchart depicting the study procedure. Subjects who meet the inclusion criteria and do not meet the exclusion criteria will be invited to participate in this study. An informed consent will be signed before their participation. All subjects will not be involved in the recruitment and conduct of the study.

Routine blood and PE analysis will be ordered in these subjects. PE specimens will be obtained for routine laboratory analysis, including cell count and differentiation, tumor markers, biochemistry, bacterial culture, Gram staining, cytology and nucleic acid amplification tests (NAAT). These laboratory test will be ordered by the attending clinicians independent of this study. Approximately 5-10 milliliters PE specimen will be collected simultaneously for research aims. All PE and serum specimens will be collected on admission before diagnosis. The time period between PE specimen collection and final diagnosis will be usually within one weeks, except for some subjects that need follow-up and therapy response to make diagnosis. Imaging (CT, MRI, CTPA), thoracoscopy and bronchoscopy will be ordered if necessary. The results of biomarkers will be disseminated to the

1  
2  
3  
4 subjects via email or telephone if they require.  
5  
6

### 7 8 **Statistical analysis**

9  
10 Normal distribution of continuous data will be tested by Kolmogorov-Smirnov test. For the data  
11 with normal distribution, independent t or one-way ANOVA tests will be used for comparison;  
12 Otherwise, Mann-Whitney or Kruskal-Wallis tests will be used. Chi-square test will be used to compare  
13 categorized data. Receiver operating characteristics (ROC) curve analysis will be used to evaluate the  
14 diagnostic accuracy of the investigated marker. Area under ROC curve (AUC) will be used to estimate  
15 the overall diagnostic accuracy of a marker. AUCs of markers will be compared by the approach  
16 proposed by Delong et al [28]. The optimal threshold will be determined with the method proposed by  
17 Pepe et al. [29] or maximum Youden index. Subjects who have multiple etiologies will be categorized  
18 into the disease group if the corresponding etiology has been proved, regardless of the etiology is  
19 primary or secondary. Multivariable logistic regression model, net reclassification index (NRI) and  
20 integrated discriminatory index (IDI) will be used to evaluate whether a given marker provides added  
21 diagnostic information [30,31] beyond conventional diagnostic tools. Decision tree approach will be  
22 created to evaluate the preferred diagnostic strategy. All analyses will be performed with SPSS 18.0  
23 (IBM Corporation, Chicago, United States), Sigmaplot 12.0 (Systat Software, Inc., San Jose, CA),  
24 Graphpad Prism 6.0 (GraphPad Software, La Jolla, CA) and R (<http://www.r-project.org>).  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

### 41 **Discussion**

42  
43 With the advance of omics approaches and basic researches, accumulated markers have been  
44 identified for exploring the etiology of PE. Under such a condition, it is valuable to evaluate the  
45 diagnostic accuracy of these markers rigorously. Although several studies have been performed on this  
46 topic [10,32,33], the result of these study remains needs to be validated. This is because that the  
47 diagnostic accuracy of a given marker may be affected by the disease spectrum of study cohort [34].  
48 Besides, majority previous studies only evaluated the diagnostic accuracy of single marker and not  
49 compared it with other promising markers. Furthermore, whether multiple markers strategy can improve  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 the diagnostic accuracy remains largely unknown. The aim of SIMPLE study was to: (i) evaluate the  
5  
6 diagnostic accuracy of biomarkers when used alone; (ii) compare the diagnostic accuracy of two or  
7  
8 more biomarkers in a head-to-head manner; (iii) verify whether a novel biomarker can provide added  
9  
10 diagnostic information beyond traditional promising biomarkers.

11  
12 Compared with previous studies, SIMPLE study has some strength. First, this is a registered,  
13  
14 prospective, double-blind study. Therefore, the results of this study may be more reliable. Second,  
15  
16 majority of previous study did not consider the subjects with multiple etiologies and this issue will be  
17  
18 considered by SIMPLE study. Third, only limited studies have investigated whether a novel marker  
19  
20 could provide added diagnostic information beyond traditional markers. In SIMPLE study, we will  
21  
22 investigate this issue with IDI and NRI, two widely-accepted statistical methods.

23  
24 Some potential biomarkers can be investigated in SIMPLE study. Here, I just give some examples.  
25  
26 Previous studies have indicated that presepsin is a useful diagnostic marker for bacterial infected  
27  
28 diseases [35,36]; nevertheless, it remains unknown whether presepsin in serum or PE is useful for  
29  
30 pneumonia diagnosis in patients with PE. Serum mid-regional pro-atrial natriuretic peptide (MR-  
31  
32 proANP) has been reported to have high diagnostic accuracy for HF [37]. However, only one study has  
33  
34 investigated the diagnostic accuracy of MR-proANP in PE for HF [22], and the results of this study  
35  
36 need to be validated.

37  
38 SIMPLE study has some limitations. First, this is the single center study and representativeness of  
39  
40 study cohort is a limitation. Second, because not all subjects will receive the same reference standard,  
41  
42 differential verification bias [38,39] is also a problem. Third, because it is not ethical to let all subjects  
43  
44 receiving all diagnostic tools once a diagnosis has been made, partial verification bias can not be avoided.  
45  
46 Indeed, establishing one diagnosis does exclude other etiologies.

47  
48 Taken together, SIMPLE study is a prospective, double-blind diagnostic study aims to investigate  
49  
50 the diagnostic accuracy of serum and PE markers. Although it has some limitations, we believe that this  
51  
52 study will provide a new insight into the PE etiological diagnosis.  
53

#### 54 **Authors' contributions**

55  
56  
57  
58  
59  
60

1  
2  
3  
4 Z.D. Hu conceived and designed the study; L Zhang, P.H. Ouyang and P Li provided administrative  
5 support; L Zhang, P.H. Ouyang, P Li, L Yan and Y.Q. Han drafted the manuscript. Z.D. Hu critically  
6 revised the manuscript; all authors approved the final version of the manuscript.  
7  
8

### 9 **Competing interests**

10 None declared.

### 11 **Acknowledgements**

12 We thank the clinicians in the Department of Respiratory and Critical Care Medicine and technicians  
13 in the Department of Laboratory Medicine for their support. We also thank the subjects who  
14 participant in this study.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24

### 25 **References**

- 26  
27 1 Porcel JM, Esquerda A, Vives M, *et al.* Etiology of pleural effusions: analysis of more than 3,000  
28 consecutive thoracenteses. *Arch Bronconeumol* 2014;50:161–5.  
29  
30 2 Wang X-J, Yang Y, Wang Z, *et al.* Efficacy and Safety of Diagnostic Thoracoscopy in  
31 Undiagnosed Pleural Effusions. *Respiration* 2015;90:251–5.  
32  
33 3 Porcel JM, Azzopardi M, Koegelenberg CF, *et al.* The diagnosis of pleural effusions. *Expert Rev*  
34 *Respir Med* 2015;9:801–15.  
35  
36 4 Beaudoin S, Gonzalez A V. Evaluation of the patient with pleural effusion. *Can Med Assoc J*  
37 2018;190:E291–5.  
38  
39 5 Assawasaksakul T, Boonsarnsuk V, Incharoen P. A comparative study of conventional cytology  
40 and cell block method in the diagnosis of pleural effusion. *J Thorac Dis* 2017;9:3161–7.  
41  
42 6 Conde MB, Loivos AC, Rezende VM, *et al.* Yield of sputum induction in the diagnosis of pleural  
43 tuberculosis. *Am J Respir Crit Care Med* 2003;167:723–5.  
44  
45 7 Valdés L, Alvarez D, San José E, *et al.* Tuberculous pleurisy: a study of 254 patients. *Arch Intern*  
46 *Med* 1998;158:2017–21.  
47  
48 8 Shivakumarswamy U, Karigowdar M, Arakeri S, *et al.* Diagnostic utility of the cell block method  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4 versus the conventional smear study in pleural fluid cytology. *J Cytol* 2012;29:11.
- 5  
6 9 Kastelik JA. Management of Malignant Pleural Effusion. *Lung* 2013;191:165–75.
- 7  
8 10 Wang W, Zhou Q, Zhai K, *et al.* Diagnostic accuracy of interleukin 27 for tuberculous pleural  
9  
10 effusion: Two prospective studies and one meta-analysis. *Thorax* 2018;73:240–7.
- 11  
12 11 Jiang J, Shi HZ, Liang QL, *et al.* Diagnostic value of interferon-gamma in tuberculous pleurisy: a  
13  
14 metaanalysis. *Chest* 2007;131:1133–41.
- 15  
16 12 Liang Q-L, Shi H-Z, Wang K, *et al.* Diagnostic accuracy of adenosine deaminase in tuberculous  
17  
18 pleurisy: A meta-analysis. *Respir Med* 2008;102:744–54.
- 19  
20 13 Han ZJ, Wu XD, Cheng JJ, *et al.* Diagnostic accuracy of natriuretic peptides for heart failure in  
21  
22 patients with pleural effusion: A systematic review and updated meta-Analysis. *PLoS One*  
23  
24 2015;10:e0134376.
- 25  
26 14 Zhou Q, Ye ZJ, Su Y, *et al.* Diagnostic value of N-terminal pro-brain natriuretic peptide for pleural  
27  
28 effusion due to heart failure: a meta-analysis. *Heart* 2010;96:1207–11.
- 29  
30 15 Hu ZD, Liu XF, Liu XC, *et al.* Diagnostic accuracy of osteopontin for malignant pleural  
31  
32 mesothelioma: a systematic review and meta-analysis. *Clin Chim Acta* 2014;433:44–8.
- 33  
34 16 Liang Q-L, Shi H-Z, Qin X-J, *et al.* Diagnostic accuracy of tumour markers for malignant pleural  
35  
36 effusion: a meta-analysis. *Thorax* 2008;63:35–41.
- 37  
38 17 He C, Wang B, Li D, *et al.* Performance of procalcitonin in diagnosing parapneumonic pleural  
39  
40 effusions. *Medicine (Baltimore)* 2017;96:e7829.
- 41  
42 18 Zou M-X, Zhou R-R, Wu W-J, *et al.* The use of pleural fluid procalcitonin and C-reactive protein  
43  
44 in the diagnosis of parapneumonic pleural effusions: a systemic review and meta-analysis. *Am J*  
45  
46 *Emerg Med* 2012;30:1907–14.
- 47  
48 19 Zhai K, Lu Y, Shi H-Z. Tuberculous pleural effusion. *J Thorac Dis* 2016;8:E486–94.
- 49  
50 20 Trajman A, Pai M, Dheda K, *et al.* Novel tests for diagnosing tuberculous pleural effusion: what  
51  
52 works and what does not? *Eur Respir J* 2008;31:1098–106.
- 53  
54 21 Porcel JM. Advances in the diagnosis of tuberculous pleuritis. *Ann Transl Med* 2016;4:282.
- 55  
56 22 Porcel JM, Bielsa S, Morales-Rull JL, *et al.* Comparison of pleural N-terminal pro-B-type


- natriuretic peptide, midregion pro-atrial natriuretic peptide and mid-region pro-adrenomedullin for the diagnosis of pleural effusions associated with cardiac failure. *Respirology* 2013;18:540–5.
- 23 Kolditz M, Halank M, Schiemanck CS, *et al.* High diagnostic accuracy of NT-proBNP for cardiac origin of pleural effusions. *Eur Respir J* 2006;28:144–50.
- 24 Liao H, Na MJ, Dikensoy O, *et al.* Diagnostic value of pleural fluid N-terminal pro-brain natriuretic peptide levels in patients with cardiovascular diseases. *Respirology* 2008;13:53–7.
- 25 Konstantinides S V., Torbicki A, Agnelli G, *et al.* 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. *Eur Heart J* 2014;35:3033–80.
- 26 Bintcliffe OJ, Hooper CE, Rider IJ, *et al.* Unilateral pleural effusions with more than one apparent etiology: A prospective observational study. *Ann Am Thorac Soc* 2016;13:1050–6.
- 27 Walker S, Maskell N. Identification and management of pleural effusions of multiple aetiologies. *Curr Opin Pulm Med* 2017;23:339–45.
- 28 DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. *Biometrics* 1988;44:837–45.
- 29 Pepe MS, Janes H, Li CI, *et al.* Early-Phase Studies of Biomarkers: What Target Sensitivity and Specificity Values Might Confer Clinical Utility? *Clin Chem* 2016;62:737–42.
- 30 Moons KG, de Groot JA, Linnet K, *et al.* Quantifying the added value of a diagnostic test or marker. *Clin Chem* 2012;58:1408–17.
- 31 Pencina MJ, D’Agostino Sr. RB, D’Agostino Jr. RB, *et al.* Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. *Stat Med* 2008;27:112–57.
- 32 Chung W, Jung Y, Lee K, *et al.* CXCR3 ligands in pleural fluid as markers for the diagnosis of tuberculous pleural effusion. *Int J Tuberc Lung Dis* 2017;21:1300–6.
- 33 Pass HI, Levin SM, Harbut MR, *et al.* Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. *N Engl J Med* 2012;367:1417–27.
- 34 Linnet K, Bossuyt PM, Moons KG, *et al.* Quantifying the Accuracy of a Diagnostic Test or Marker. *Clin Chem* 2012;58:1292–301.

- 1  
2  
3  
4 35 Wu J, Hu L, Zhang G, *et al.* Accuracy of Presepsin in Sepsis Diagnosis: A Systematic Review and  
5  
6  
7  
8 36 Zhang J, Hu ZD, Song J, *et al.* Diagnostic Value of Presepsin for Sepsis: A Systematic Review and  
9  
10  
11  
12 37 Hu Z, Han Z, Huang Y, *et al.* Diagnostic power of the mid-regional pro-atrial natriuretic peptide for  
13  
14  
15  
16 38 de Groot JA, Bossuyt PM, Reitsma JB, *et al.* Verification problems in diagnostic accuracy studies:  
17  
18  
19  
20 39 Whiting P, Rutjes AW, Reitsma JB, *et al.* Sources of variation and bias in studies of diagnostic  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 **Figure legend**

5 **Figure 1.** Flowchart of study procedure.  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60





# BMJ Open

## Protocol for a Study Investigating Markers in Pleural Effusion (SIMPLE study): A prospective and double-blind diagnostic study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-027287.R1
Article Type:	Protocol
Date Submitted by the Author:	25-Mar-2019
Complete List of Authors:	Han, Yan-Qiu; the Affiliated Hospital of Inner Mongolia Medical University, Department of Laboratory Medicine Yan, Li; the Affiliated Hospital of Inner Mongolia Medical University, Department of Respiratory and Critical Care Medicine Li, Peng; the Affiliated Hospital of Inner Mongolia Medical University, Department of Laboratory Medicine Zhang, Lei; the Affiliated Hospital of Inner Mongolia Medical University, Department of Laboratory Medicine Ouyang, Pei-Heng; the Affiliated Hospital of Inner Mongolia Medical University, Department of Laboratory Medicine Hu, Zhi-De; the Affiliated Hospital of Inner Mongolia Medical University, Department of Laboratory Medicine
<b>Primary Subject Heading</b>:	Diagnostics
Secondary Subject Heading:	Respiratory medicine
Keywords:	Diagnostic accuracy test, Pleural effusion, Markers

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 **Protocol for a Study Investigating Markers in PLeural Effusion (SIMPLE study): A**  
5  
6 **prospective and double-blind diagnostic study**  
7  
8

9 Yan-Qiu Han<sup>1</sup>, Li Yan<sup>2</sup>, Peng Li<sup>1</sup>, Lei Zhang<sup>1</sup>, Pei-Heng Ouyang<sup>1</sup>, Zhi-De Hu<sup>1,\*</sup>  
10  
11

12  
13 <sup>1</sup> Department of Laboratory Medicine, the Affiliated Hospital of Inner Mongolia Medical  
14  
15 University, Hohhot, China.  
16

17 <sup>2</sup> Department of Respiratory and Critical Care Medicine, the Affiliated Hospital of Inner Mongolia  
18  
19 Medical University, Hohhot, China.  
20  
21

22  
23 **Correspondence to:** Dr Zhi-De Hu; [hzdjlj81@163.com](mailto:hzdjlj81@163.com)  
24  
25

26  
27 Word count: 2353  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Abstract**

**Introduction:** Serum and fluid laboratory biomarkers are valuable for exploring the etiologies of pleural effusion because of their relative non-invasiveness, low cost, objective result and short turn-around time. The diagnostic accuracy of these potential biomarkers needs to be rigorously evaluated before their widespread application in clinical practice. Here, we plan to perform a Study Investigating Markers in PLeural Effusion (SIMPLE study).

**Methods and analysis:** This is a prospective and double-blind clinical trial which is being performed at the Affiliated Hospital of Inner Mongolia Medical University, China. Adult patients admitted for the evaluation of etiology of pleural effusion from September 2018 to July 2021 will be enrolled after informed consent. Pleural fluid and serum specimens will be collected and stored at  $-80^{\circ}\text{C}$  for the laboratorial analysis. The final diagnosis will be concurred with further imaging, microbiology, cytology and biopsy if needed. The results of investigated laboratory markers will be unknown to the clinicians who will make diagnosis and the clinical diagnoses will be unknown to the laboratory technicians who will determine markers. The diagnostic accuracy of investigated markers will be assessed using receiver operating characteristics (ROC) curve analysis, multivariable logistic regression model, net reclassification index (NRI) and integrated discriminatory index (IDI).

**Ethics:** The study is approved by the Ethic Committee of the Affiliated Hospital of Inner Mongolia Medical University (NO: 2018011).

**Study registration:** The study is also registered with the Chinese Clinical Trial Registry platform, with a registration number of ChiCTR1800017449.

**Keywords:** Markers; Pleural effusion; Diagnostic accuracy test

**Strengths and limitations of this study**

- A prospectively designed trial evaluating the diagnostic value of pleural fluid and serum markers in subjects with pleural effusion.
- Double-blinded: the clinicians making diagnosis will be masked to the laboratory results of markers, and the laboratory technician determining markers will be masked to the clinical diagnosis of the subjects.
- Multiple laboratory markers for various target diseases will be studied.
- Multiple differential diagnosis will be considered.
- The main limitations of the study are: single-center design and there is a possibility of patients selection bias.

## Introduction

Pleural effusion (PE) is a frequent problem in the clinical practice and can be caused by various disorders such as congestive heart failure (CHF), liver and pancreatic diseases, diseases of lungs such as malignancy, tuberculosis and pneumonia etc. [1,2]. An accurate and timely diagnosis is a prerequisite for PE management to evaluate its cause. Light's criteria, which encompass serum and pleural fluid biochemical analyses, are commonly used in the clinical practice to distinguish between the exudative and transudative pleural effusions [3]. Although Light's criteria has high sensitivity for detecting exudative pleural effusion but occasionally it cannot be used to differentiate the underlying causes, such as infections and malignancies [4]. Currently, several tools are available for exploring the etiology of PE, including thoracoscopy, chest imaging especially CT scan, cytology and bacterial culture [5,6]. Thoracoscopy is one of the most widely-used and has a good diagnostic performance for various thoracic disorders. Nevertheless, a previous study indicated that approximately 7% of patients with PE remain undiagnosed after thoracoscopy [2]. Besides, thoracoscopy is an invasive tool associated with procedure related complications. The microbiological and cytological examinations have high specificity but their diagnostic sensitivities are unsatisfactory [7–10]. Besides, the diagnostic accuracy of these tools is largely operator and pathologist dependent [11]. Bacterial culture has high diagnostic specificity for infectious causes of PE ; however, the long turnaround time (TAT) limits its application in clinical setting.

By contrast, serum and pleural fluid biochemical analyses have some advantages including but not limited to low cost, short TAT, easy standardization with less operator or observer variations. Indeed, some pleural fluid and serum markers have shown extremely high diagnostic accuracy in patients with PE. For instance, interleukin-27 (IL-27) [12], interferon-gamma [13] and adenosine deaminase (ADA) [14] pleural fluid levels for tuberculous PE, and serum N-terminal pro-brain natriuretic peptide (NT-proBNP) for CHF [4,15]. However, for malignant and infectious diseases, the diagnostic accuracy of available markers such as tumor markers [4,16,17], procalcitonin (PCT) [18] and C-reactive protein (CRP) [19] is unsatisfactory. Therefore, further researches are needed to identify novel markers in PE with increased diagnostic accuracy.

Here, we plan to perform a prospective, double-blind diagnostic trial, named A Study Investigating Markers in PLeural Effusion (SIMPLE study). The aim of SIMPLE is to: (i) evaluate the diagnostic accuracy of serum and pleural fluid markers when used alone; (ii) compare the

1  
2  
3  
4 diagnostic accuracy of two or more markers in a head-to-head manner; (iii) verify whether a novel  
5 marker can provide added diagnostic information beyond available traditional markers.  
6  
7

## 8 9 **Method**

### 10 **Trial registration and foundation**

11  
12  
13 All subjects, or their guardians, will be provided a full informed consent before inclusion in  
14 the study. The study has been registered with the Chinese Clinical Trial Registry platform  
15 (<http://www.chictr.org.cn/index.aspx>. Registration number: ChiCTR1800017449). Currently, this  
16 study is not supported by any grant; however, it may be supported by one or more grants from the  
17 Affiliated Hospital of Inner Mongolia Medical University or the Chinese government in future. The  
18 funders will not be involved in study design, sample collection, and data analyses.  
19  
20  
21  
22  
23  
24  
25  
26

### 27 **Subject enrollment and specimen collection**

28  
29 Subjects who will be admitted to our hospital for an evaluation of the etiology of the pleural  
30 effusion will be eligible for enrollment. The presence of PE will be evaluated first by clinical  
31 examination and then further confirmed by chest imaging such as CT scan or ultrasound. The  
32 exclusion criteria are: (i) age less than 18 years; (ii) with a known diagnosis of a disease that could  
33 cause PE during the last three months; (iii) pregnancy; (iv) refused to sign informed consent; (v)  
34 with comorbidities that can prevent pleural fluid collection; (vi) subject dies during hospitalisation  
35 without collection of pleural fluid and serum specimens; (vii) death of a subject during hospital stay  
36 before the final diagnosis; (viii) patients admitted without PE but developed PE after admission.  
37  
38  
39  
40  
41  
42  
43

44  
45 Pleural fluid specimen collection will be initiated after obtaining informed consent by the  
46 patient. Approximately 5-10 milliliters of pleural fluid specimen will be collected in a tube that does  
47 not contain any anticoagulant. The specimen will be sent to laboratory within 2 hours and  
48 centrifuged at 1200g for 10 minutes. The supernatants of the specimen will then be transferred to  
49 10 Eppendorf tubes (510 µl tube) and immediately frozen at -80°C for later use. A serum sample  
50 will be collected from the same patient within 24 hours before or after the pleural fluid collection to  
51 be frozen at -80 °C if available. A case report form will be used to record demographic and clinical  
52 details of the subjects, such as age, sex, side of PE (left-, right- or two-sided effusion), smoking  
53 history, conventional laboratory tests and microbiological findings.  
54  
55  
56  
57  
58  
59  
60

All subjects will be enrolled by a pulmonologist (L Yan). The subjects will be not consecutively enrolled because they may: (i) refuse to sign the informed consent; (ii) be admitted at weekend when Dr. Yan is not on duty; (iii) not be admitted to the Department of Respiratory and Critical Care Medicine of our institution.

The laboratory technician who determines the concentration of investigated markers will be blinded to clinical presentations of the subjects.

### Sample size estimation

As this is not a hypothesis-driven research and no new target disease or marker is proposed, we did not estimate the sample size before subjects' enrollment. The study execute time will last from September 2018 to July 2021. It is estimated that 200 to 300 subjects will be enrolled.

### Final diagnosis

This is an observational study that will not affect the further management of the enrolled subjects. The clinicians will decide the further diagnostic, treatment and management independent of this study. The etiologies of PE are diverse and the diagnostic criteria for the major diseases are listed in **Table 1**. The final diagnosis will be made by two researchers independently (L Yan and ZD Hu) and the results of investigated markers will not be known by them when making diagnosis.

**Table 1** Diagnostic criteria for major diseases related to PE

Etiology	Diagnostic criteria
Tuberculous	Identification of <i>Mycobacterium tuberculosis</i> in the sputum, pleural fluid, or pleural biopsy specimens [20], either by microscopy or cultures. In some cases with adequate clinical context, the diagnosis can be made with presence of granuloma in the parietal pleura, good response to anti-tuberculosis treatment, elevated level of pleural fluid adenosine deaminase or positive nucleic acid amplification tests (NAATs) [20–22].



Congestive heart failure	Typical clinical picture of CHF including the Framingham score, medical history and physical examination, the response to diuretic therapy, typical CHF features on chest X-ray, the echocardiographic evidence of left ventricular systolic dysfunction [15,23–25].
Malignant diseases	Identification of cancer cells in pleural fluid, sputum or bronchoalveolar lavage fluid by cytological examination, ultrasound or thoracoscopy-guided pleural biopsy [5,24].
Parapneumonic effusion	Typical clinical and radiological evidences of pneumonia, or a positive bacterial culture from pleural fluid, or good response to antibiotic therapy [5,24].
Pulmonary embolism	Computed tomographic pulmonary angiography (CTPA) [26].

Given that approximately 30% of PEs have more than one etiology and the most common secondary cause is CHF [27,28]. Therefore, all patients will be evaluated for concomitant presence of CHF. For some subjects, the differential diagnosis can change during their admission only the diagnosis at the time of specimen collection will be used. We also realize that a confirmed diagnosis is not possible in all cases with PE at the time of discharge. This can be due to the fact that some subjects might refuse to receive further diagnostic invasive approaches such as thoracoscopy. The number of these subjects will be recorded and reported. The patients without final diagnosis will be excluded from the final analysis or will be considered as control in the data analysis.

### Patient and public involvement

**Figure 1** is a flowchart depicting the study procedure. Subjects who will meet the inclusion and exclusion criteria will be invited to participate in this study. An informed consent will be signed before their participation. All subjects will not be involved in the recruitment and conduct of the study.

Routine serum and pleural fluid analysis will be ordered for these subjects. Pleural fluid specimens will be obtained for routine laboratory analysis, including cell count and differentiation, tumor markers, biochemistry, bacterial culture, Gram staining, cytology and nucleic acid amplification tests (NAAT). These laboratory tests will be ordered by the attending clinicians

1  
2  
3  
4 independent of this study. Approximately 5-10 milliliters of pleural fluid specimen will be collected  
5  
6 simultaneously for research aims. All fluid and serum specimens will be collected at the time of  
7  
8 admission before final diagnosis. The time period between the pleural fluid specimen collection and  
9  
10 final diagnosis will be usually within one weeks, except for some subjects that need follow-up and  
11  
12 therapy response to make diagnosis. Imaging (CT, MRI, CTPA), thoracoscopy and bronchoscopy  
13  
14 will be ordered if necessary. The results of markers will be disseminated to the subjects via email  
15  
16 or telephone upon request after the conclusion of the study.

### 17 **Dissemination and ethics**

18  
19 The results of SIMPLE will be submitted to international scientific peer-reviewed journals or  
20  
21 conferences in laboratory medicine of respiratory medicine, thoracic diseases. This study has been  
22  
23 approved by the Ethic Committee of the Affiliated Hospital of Inner Mongolia Medical University  
24  
25 (NO: 2018011).

### 26 **Patient and public involvement statement**

27  
28 All subjects in SIMPLE study will not directly involved in the study design, recruitment and  
29  
30 study conduction. There is no public involvement.

### 31 **Statistical analysis**

32  
33 Normal distribution of continuous data will be tested by Kolmogorov-Smirnov test. For the  
34  
35 data with normal distribution, independent t-test or one-way ANOVA will be used for comparison;  
36  
37 Otherwise, Mann-Whitney or Kruskal-Wallis tests will be used. Chi-square test will be used to  
38  
39 compare categorized data. Receiver operating characteristics (ROC) curve analysis will be used to  
40  
41 evaluate the diagnostic accuracy of the investigated markers. Area under ROC curve (AUC) will be  
42  
43 used to estimate the overall diagnostic accuracy of a markers. AUCs of markers will be compared  
44  
45 by the approach proposed by DeLong et al [29]. The optimal threshold will be determined with the  
46  
47 method proposed by Pepe et al. [30] or maximum Youden index. When evaluating the diagnostic  
48  
49 accuracy of a marker for a given disease, the subjects with this disease will be categorized into a  
50  
51 disease group, regardless of whether other etiologies co-occur. Multivariable logistic regression  
52  
53 model, net reclassification index (NRI) and integrated discriminatory index (IDI) will be used to  
54  
55 evaluate whether a given marker provides added diagnostic information [31,32] beyond  
56  
57 conventional diagnostic tools and clinical details (e.g. side information, age, sex, smoking history).  
58  
59 Decision tree approach and decision curve analysis [33] will be created to evaluate the preferred  
60

1  
2  
3  
4 diagnostic strategy. All analyses will be performed with SPSS 18.0 (IBM Corporation, Chicago,  
5 United States), Sigmaplot 12.0 (Systat Software, Inc., San Jose, CA), Graphpad Prism 6.0  
6 (GraphPad Software, La Jolla, CA) and R (<http://www.r-project.org>).  
7  
8  
9

## 10 11 **Discussion**

12  
13 Multiple new diagnostic markers have been identified in the evaluation of PE with the  
14 advancement in omics approach and basic research. Therefore, it is valuable to evaluate the  
15 diagnostic accuracy of these markers rigorously. Although several studies have been performed on  
16 this topic [12,34,35], the result of these studies need to be validated. This is because that the  
17 diagnostic accuracy of a given marker may be affected by the disease spectrum of a study cohort  
18 [36]. Besides, majority of previous published studies evaluated only the diagnostic accuracy of  
19 single marker, and did not compare it with other promising markers. Furthermore, whether multi-  
20 marker strategy can improve the diagnostic accuracy remains largely unknown.  
21  
22

23  
24 Compared with previous studies, SIMPLE study has some strength. First, this is a registered,  
25 prospective, double-blind study. Therefore, the results of this study are more reliable. Second,  
26 majority of the previous studies did not consider the subjects with multiple etiologies of PE and this  
27 issue will be considered by SIMPLE study. Third, only limited studies have investigated whether a  
28 novel marker could provide added diagnostic information beyond traditional markers. In SIMPLE  
29 study, we will investigate this issue with IDI and NRI, although they have some shortcomings [37–  
30 40].  
31  
32

33  
34 Multiple potential serum and fluid markers will be investigated in the SIMPLE study. Previous  
35 studies have indicated that presepsin is a useful diagnostic marker for bacterial infection [41,42];  
36 nevertheless, it remains unknown whether presepsin in serum or pleural fluid is useful for the  
37 diagnosis of parapneumonic effusion. Serum mid-regional pro-atrial natriuretic peptide (MR-  
38 proANP) has been reported to have high diagnostic accuracy for CHF [43]. However, only one  
39 study has investigated the diagnostic accuracy of MR-proANP in PE caused by CHF [23], and the  
40 results of this study need to be validated. In addition, some novel markers will also be studied, such  
41 as soluble Fas ligand [44] and interleukin 27 [12] for tuberculous pleurisy, soluble B7-H4 [45] and  
42 human epididymis 4 (HE4) [46] for malignant effusion. The results of SIMPLE study will be  
43 reported in accordance with the Standards for Reporting of Diagnostic Accuracy Studies (STARD)  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 guideline [47]. For researches with multivariable prediction model, the report will comply with  
5  
6 Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis  
7  
8 (TRIPOD) statement [48].

9  
10 SIMPLE study has some limitations. First, this is a single center study and representativeness  
11  
12 of the study cohort is a limitation. Second, because it is not ethical to let all subjects receiving all  
13  
14 diagnostic tools once a diagnosis has been made, partial verification bias can not be avoided. Indeed,  
15  
16 establishing one diagnosis does exclude other etiologies. Third, the prognostic value of markers will  
17  
18 not be evaluated in this study.

19  
20 Taken together, SIMPLE study is a prospective, double-blind diagnostic study aims to  
21  
22 investigate the diagnostic accuracy of serum and pleural fluid markers. Although it has some  
23  
24 limitations, we believe that this study will provide a new insight into the PE etiological field.

### 25 26 27 **Authors' contributions**

28  
29 Z.D. Hu conceived and designed the study; L Zhang, P.H. Ouyang and P Li provided administrative  
30  
31 support; L Zhang, P.H. Ouyang, P Li, L Yan and Y.Q. Han drafted the manuscript. Z.D. Hu critically  
32  
33 revised the manuscript; all authors approved the final version of the manuscript.

### 34 35 **Competing interests**

36  
37 None declared.

### 38 39 **Acknowledgements**

40  
41 We thank the clinicians in the Department of Respiratory and Critical Care Medicine and  
42  
43 technicians in the Department of Laboratory Medicine for their support. We thank Dr. Hemant  
44  
45 Goyal MD FACP from Mercer University School of Medicine for manuscript editing.

46  
47  
48 **Funding:** None at current stage.

### 49 50 51 **References**

- 52  
53  
54 1 Porcel JM, Esquerda A, Vives M, *et al.* Etiology of pleural effusions: analysis of more than  
55  
56 3,000 consecutive thoracenteses. *Arch Bronconeumol* 2014;**50**:161–5.  
57  
58 2 Wang X-J, Yang Y, Wang Z, *et al.* Efficacy and Safety of Diagnostic Thoracoscopy in  
59  
60 Undiagnosed Pleural Effusions. *Respiration* 2015;**90**:251–5.

- 1  
2  
3  
4 3 Light RW, Macgregor MI, Luchsinger PC, *et al.* Pleural effusions: the diagnostic separation of  
5 transudates and exudates. *Ann Intern Med* 1972;**77**:507–13.  
6  
7  
8 4 Zhou Q, Ye ZJ, Su Y, *et al.* Diagnostic value of N-terminal pro-brain natriuretic peptide for  
9 pleural effusion due to heart failure: a meta-analysis. *Heart* 2010;**96**:1207–11.  
10  
11 5 Porcel JM, Azzopardi M, Koegelenberg CF, *et al.* The diagnosis of pleural effusions. *Expert*  
12 *Rev Respir Med* 2015;**9**:801–15.  
13  
14  
15 6 Beaudoin S, Gonzalez A V. Evaluation of the patient with pleural effusion. *Can Med Assoc J*  
16 2018;**190**:E291–5.  
17  
18  
19 7 Assawasaksakul T, Boonsarngsuk V, Incharoen P. A comparative study of conventional  
20 cytology and cell block method in the diagnosis of pleural effusion. *J Thorac Dis* 2017;**9**:3161–  
21 7.  
22  
23  
24  
25 8 Conde MB, Loivos AC, Rezende VM, *et al.* Yield of sputum induction in the diagnosis of  
26 pleural tuberculosis. *Am J Respir Crit Care Med* 2003;**167**:723–5.  
27  
28  
29 9 Valdés L, Alvarez D, San José E, *et al.* Tuberculous pleurisy: a study of 254 patients. *Arch*  
30 *Intern Med* 1998;**158**:2017–21.  
31  
32  
33 10 Shivakumarswamy U, Karigowdar M, Arakeri S, *et al.* Diagnostic utility of the cell block  
34 method versus the conventional smear study in pleural fluid cytology. *J Cytol* 2012;**29**:11.  
35  
36  
37 11 Kastelik JA. Management of Malignant Pleural Effusion. *Lung* 2013;**191**:165–75.  
38  
39 12 Wang W, Zhou Q, Zhai K, *et al.* Diagnostic accuracy of interleukin 27 for tuberculous pleural  
40 effusion: Two prospective studies and one meta-analysis. *Thorax* 2018;**73**:240–7.  
41  
42  
43 13 Jiang J, Shi HZ, Liang QL, *et al.* Diagnostic value of interferon-gamma in tuberculous pleurisy:  
44 a metaanalysis. *Chest* 2007;**131**:1133–41.  
45  
46  
47 14 Liang Q-L, Shi H-Z, Wang K, *et al.* Diagnostic accuracy of adenosine deaminase in  
48 tuberculous pleurisy: A meta-analysis. *Respir Med* 2008;**102**:744–54.  
49  
50  
51 15 Han ZJ, Wu XD, Cheng JJ, *et al.* Diagnostic accuracy of natriuretic peptides for heart failure in  
52 patients with pleural effusion: A systematic review and updated meta-Analysis. *PLoS One*  
53 2015;**10**:e0134376.  
54  
55  
56 16 Hu Z-DD, Liu X-CFX-FC, Liu X-CFX-FC, *et al.* Diagnostic accuracy of osteopontin for  
57 malignant pleural mesothelioma: a systematic review and meta-analysis. *Clin Chim Acta*  
58 2014;**433**:44–8.  
59  
60

- 1  
2  
3  
4 17 Liang Q-L, Shi H-Z, Qin X-J, *et al.* Diagnostic accuracy of tumour markers for malignant  
5 pleural effusion: a meta-analysis. *Thorax* 2008;**63**:35–41.  
6  
7 18 He C, Wang B, Li D, *et al.* Performance of procalcitonin in diagnosing parapneumonic pleural  
8 effusions. *Medicine (Baltimore)* 2017;**96**:e7829.  
9  
10 19 Zou M-X, Zhou R-R, Wu W-J, *et al.* The use of pleural fluid procalcitonin and C-reactive  
11 protein in the diagnosis of parapneumonic pleural effusions: a systemic review and meta-  
12 analysis. *Am J Emerg Med* 2012;**30**:1907–14.  
13  
14 20 Zhai K, Lu Y, Shi H-Z. Tuberculous pleural effusion. *J Thorac Dis* 2016;**8**:E486–94.  
15  
16 21 Trajman A, Pai M, Dheda K, *et al.* Novel tests for diagnosing tuberculous pleural effusion:  
17 what works and what does not? *Eur Respir J* 2008;**31**:1098–106.  
18  
19 22 Porcel JM. Advances in the diagnosis of tuberculous pleuritis. *Ann Transl Med* 2016;**4**:282.  
20  
21 23 Porcel JM, Bielsa S, Morales-Rull JL, *et al.* Comparison of pleural N-terminal pro-B-type  
22 natriuretic peptide, midregion pro-atrial natriuretic peptide and mid-region pro-adrenomedullin  
23 for the diagnosis of pleural effusions associated with cardiac failure. *Respirology* 2013;**18**:540–  
24 5.  
25  
26 24 Kolditz M, Halank M, Schiemanck CS, *et al.* High diagnostic accuracy of NT-proBNP for  
27 cardiac origin of pleural effusions. *Eur Respir J* 2006;**28**:144–50.  
28  
29 25 Liao H, Na MJ, Dikensoy O, *et al.* Diagnostic value of pleural fluid N-terminal pro-brain  
30 natriuretic peptide levels in patients with cardiovascular diseases. *Respirology* 2008;**13**:53–7.  
31  
32 26 Konstantinides S V., Torbicki A, Agnelli G, *et al.* 2014 ESC Guidelines on the diagnosis and  
33 management of acute pulmonary embolism. *Eur. Heart J.* 2014;**35**:3033–80.  
34  
35 27 Bintlcliffe OJ, Hooper CE, Rider IJ, *et al.* Unilateral pleural effusions with more than one  
36 apparent etiology: A prospective observational study. *Ann Am Thorac Soc* 2016;**13**:1050–6.  
37  
38 28 Walker S, Maskell N. Identification and management of pleural effusions of multiple  
39 aetiologies. *Curr Opin Pulm Med* 2017;**23**:339–45.  
40  
41 29 DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more  
42 correlated receiver operating characteristic curves: a nonparametric approach. *Biometrics*  
43 1988;**44**:837–45.  
44  
45 30 Pepe MS, Janes H, Li CI, *et al.* Early-Phase Studies of Biomarkers: What Target Sensitivity  
46 and Specificity Values Might Confer Clinical Utility? *Clin Chem* 2016;**62**:737–42.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4 31 Moons KG, de Groot JA, Linnet K, *et al.* Quantifying the added value of a diagnostic test or  
5 marker. *Clin Chem* 2012;**58**:1408–17.  
6  
7  
8 32 Pencina MJ, D’Agostino Sr. RB, D’Agostino Jr. RB, *et al.* Evaluating the added predictive  
9 ability of a new marker: from area under the ROC curve to reclassification and beyond. *Stat*  
10 *Med* 2008;**27**:112–57.  
11  
12  
13 33 Vickers AJ, Elkin EB. Decision Curve Analysis: A Novel Method for Evaluating Prediction  
14 Models. *Med Decis Mak* 2006;**26**:565–74.  
15  
16  
17 34 Chung W, Jung Y, Lee K, *et al.* CXCR3 ligands in pleural fluid as markers for the diagnosis of  
18 tuberculous pleural effusion. *Int J Tuberc Lung Dis* 2017;**21**:1300–6.  
19  
20  
21 35 Pass HI, Levin SM, Harbut MR, *et al.* Fibulin-3 as a blood and effusion biomarker for pleural  
22 mesothelioma. *N Engl J Med* 2012;**367**:1417–27.  
23  
24  
25 36 Linnet K, Bossuyt PM, Moons KG, *et al.* Quantifying the Accuracy of a Diagnostic Test or  
26 Marker. *Clin Chem* 2012;**58**:1292–301.  
27  
28  
29 37 Pepe MS, Fan J, Feng Z, *et al.* The Net Reclassification Index (NRI): a Misleading Measure of  
30 Prediction Improvement Even with Independent Test Data Sets. *Stat Biosci* 2015;**7**:282–95.  
31  
32  
33 38 Gerds TA, Hilden J. Calibration of models is not sufficient to justify NRI. *Stat Med*  
34 2014;**33**:3419–20.  
35  
36  
37 39 Hilden J. Commentary: On NRI, IDI, and “good-looking” statistics with nothing  
38 underneath. *Epidemiology* 2014;**25**:265–7.  
39  
40  
41 40 Hilden J, Gerds TA. A note on the evaluation of novel biomarkers: do not rely on integrated  
42 discrimination improvement and net reclassification index. *Stat Med* 2014;**33**:3405–14.  
43  
44  
45 41 Wu J, Hu L, Zhang G, *et al.* Accuracy of Procalcitonin in Sepsis Diagnosis: A Systematic Review  
46 and Meta-Analysis. *PLoS One* 2015;**10**:e0133057.  
47  
48  
49 42 Zhang J, Hu Z-DD, Song J, *et al.* Diagnostic Value of Procalcitonin for Sepsis: A Systematic  
50 Review and Meta-Analysis. *Med* 2015;**94**:e2158.  
51  
52  
53 43 Hu Z, Han Z, Huang Y, *et al.* Diagnostic power of the mid-regional pro-atrial natriuretic  
54 peptide for heart failure patients with dyspnea: A meta-analysis. *Clin Biochem* 2012;**45**:1634–  
55 9.  
56  
57  
58 44 Wu S-H, Li C-T, Lin C-H, *et al.* Soluble Fas ligand is another good diagnostic marker for  
59 tuberculous pleurisy. *Diagn Microbiol Infect Dis* 2010;**68**:395–400.  
60

- 1  
2  
3  
4 45 Xu C, Qian L, Yu L, *et al.* Evaluation of serum and pleural levels of soluble B7-H4 in lung  
5 cancer patients with pleural effusion. *Biomarkers* 2015;**20**:271–4.  
6  
7 46 Elsammak MY, Attia A, Hassan HA, *et al.* Evaluation of pleural fluid human epididymis 4  
8 (HE4) as a marker of malignant pleural effusion. *Tumour Biol* 2012;**33**:1701–7.  
9  
10 47 Bossuyt PM, Reitsma JB, Bruns DE, *et al.* STARD 2015: An Updated List of Essential Items  
11 for Reporting Diagnostic Accuracy Studies. *Clin Chem* 2015;**61**:1446–52.  
12  
13 48 Collins GS, Reitsma JB, Altman DG, *et al.* Transparent reporting of a multivariable prediction  
14 model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. *BMJ*  
15 2015;**350**:g7594–g7594.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Figure legend**

**Figure 1.** Flowchart of study procedure.

For peer review only




Figure 1. Flowchart of study procedure.

64x90mm (300 x 300 DPI)

# BMJ Open

## Protocol for a Study Investigating Markers in PLeural Effusion (SIMPLE): A prospective and double-blind diagnostic study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-027287.R2
Article Type:	Protocol
Date Submitted by the Author:	10-May-2019
Complete List of Authors:	Han, Yan-Qiu; the Affiliated Hospital of Inner Mongolia Medical University, Department of Laboratory Medicine Yan, Li; the Affiliated Hospital of Inner Mongolia Medical University, Department of Respiratory and Critical Care Medicine Li, Peng; the Affiliated Hospital of Inner Mongolia Medical University, Department of Laboratory Medicine Zhang, Lei; the Affiliated Hospital of Inner Mongolia Medical University, Department of Laboratory Medicine Ouyang, Pei-Heng; the Affiliated Hospital of Inner Mongolia Medical University, Department of Laboratory Medicine Hu, Zhi-De; the Affiliated Hospital of Inner Mongolia Medical University, Department of Laboratory Medicine
<b>Primary Subject Heading</b>:	Diagnostics
Secondary Subject Heading:	Respiratory medicine
Keywords:	Diagnostic accuracy test, Pleural effusion, Markers

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 **Protocol for a Study Investigating Markers in PLeural Effusion (SIMPLE): A prospective**  
5  
6 **and double-blind diagnostic study**  
7  
8

9 Yan-Qiu Han<sup>1</sup>, Li Yan<sup>2</sup>, Peng Li<sup>1</sup>, Lei Zhang<sup>1</sup>, Pei-Heng Ouyang<sup>1</sup>, Zhi-De Hu<sup>1,\*</sup>  
10  
11

12  
13 <sup>1</sup> Department of Laboratory Medicine, the Affiliated Hospital of Inner Mongolia Medical  
14 University, Hohhot, China.  
15

16  
17 <sup>2</sup> Department of Respiratory and Critical Care Medicine, the Affiliated Hospital of Inner Mongolia  
18 Medical University, Hohhot, China.  
19  
20

21  
22  
23 **Correspondence to:** Dr Zhi-De Hu; [hzdjlj81@163.com](mailto:hzdjlj81@163.com)  
24  
25

26  
27 Word count: 2353  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

**Introduction:** Serum and fluid laboratory markers are valuable for exploring the etiologies of pleural effusion because of their relative non-invasiveness, low cost, objective result and short turn-around time. The diagnostic accuracy of these potential markers needs to be rigorously evaluated before their widespread application in clinical practice. Here, we plan to perform a Study Investigating Markers in PLeural Effusion (SIMPLE).

**Methods and analysis:** This is a prospective and double-blind clinical trial which is being performed at the Affiliated Hospital of Inner Mongolia Medical University, China. Adult patients admitted for the evaluation of etiology of pleural effusion from September 2018 to July 2021 will be enrolled after informed consent. Pleural fluid and serum specimens will be collected and stored at  $-80^{\circ}\text{C}$  for the laboratorial analysis. The final diagnosis will be concurred with further imaging, microbiology, cytology and biopsy if needed. The results of investigated laboratory markers will be unknown to the clinicians who will make diagnosis and the clinical diagnoses will be unknown to the laboratory technicians who will determine markers. The diagnostic accuracy of investigated markers will be assessed using receiver operating characteristics (ROC) curve analysis, multivariable logistic regression model, decision curve analysis (DCA), net reclassification index (NRI) and integrated discriminatory index (IDI).

**Ethics:** The study is approved by the Ethic Committee of the Affiliated Hospital of Inner Mongolia Medical University (NO: 2018011).

**Study registration:** The study is also registered with the Chinese Clinical Trial Registry platform, with a registration number of ChiCTR1800017449.

**Keywords:** Markers; Pleural effusion; Diagnostic accuracy test

**Strengths and limitations of this study**

- A prospectively designed trial evaluating the diagnostic value of pleural fluid and serum markers in subjects with pleural effusion.
- Double-blinded: the clinicians making diagnosis will be masked to the laboratory results of markers, and the laboratory technician determining markers will be masked to the clinical diagnosis of the subjects.
- Multiple laboratory markers for various target diseases will be studied.
- Multiple differential diagnosis will be considered.
- The main limitations of the study are: single-center design and there is a possibility of patients selection bias.

## Introduction

Pleural effusion (PE) is a frequent problem in the clinical practice and can be caused by various disorders such as congestive heart failure (CHF), liver and pancreatic diseases, diseases of lungs such as malignancy, tuberculosis and pneumonia etc. [1,2]. An accurate and timely diagnosis is a prerequisite for PE management to evaluate its cause. Light's criteria, which encompass serum and pleural fluid biochemical analyses, are commonly used in the clinical practice to distinguish between the exudative and transudative pleural effusions [3]. Although Light's criteria has high sensitivity for detecting exudative pleural effusion but occasionally it cannot be used to differentiate the underlying causes, such as infections and malignancies [4]. Currently, several tools are available for exploring the etiology of PE, including thoracoscopy, chest imaging especially CT scan, cytology and bacterial culture [5,6]. Thoracoscopy is one of the most widely-used and has a good diagnostic performance for various thoracic disorders. Nevertheless, a previous study indicated that approximately 7% of patients with PE remain undiagnosed after thoracoscopy [2]. Besides, thoracoscopy is an invasive tool associated with procedure related complications. The microbiological and cytological examinations have high specificity but their diagnostic sensitivities are unsatisfactory [7–10]. Besides, the diagnostic accuracy of these tools is largely operator and pathologist dependent [11]. Bacterial culture has high diagnostic specificity for infectious causes of PE ; however, the long turnaround time (TAT) limits its application in clinical setting.

By contrast, serum and pleural fluid biochemical analyses have some advantages including but not limited to low cost, short TAT, easy standardization with less operator or observer variations. Indeed, some pleural fluid and serum markers have shown extremely high diagnostic accuracy in patients with PE. For instance, interleukin-27 (IL-27) [12], interferon-gamma [13] and adenosine deaminase (ADA) [14] pleural fluid levels for tuberculous PE, and serum N-terminal pro-brain natriuretic peptide (NT-proBNP) for CHF [4,15]. However, for malignant and infectious diseases, the diagnostic accuracy of available markers such as tumor markers [4,16,17], procalcitonin (PCT) [18] and C-reactive protein (CRP) [19] is unsatisfactory. Therefore, further researches are needed to identify novel markers in PE with increased diagnostic accuracy.

Here, we plan to perform a prospective, double-blind diagnostic trial, named A Study Investigating Markers in PLeural Effusion (SIMPLE). The aim of SIMPLE is to: (i) evaluate the diagnostic accuracy of serum and pleural fluid markers when used alone; (ii) compare the diagnostic

1  
2  
3 accuracy of two or more markers in a head-to-head manner; (iii) verify whether a novel marker can  
4 provide added diagnostic information beyond available traditional markers.  
5  
6  
7

## 8 9 **Method**

### 10 **Trial registration and foundation**

11  
12 All subjects, or their guardians, will be provided a full informed consent before inclusion in  
13 the study. The study has been registered with the Chinese Clinical Trial Registry platform  
14 (<http://www.chictr.org.cn/index.aspx>. Registration number: ChiCTR1800017449). Currently, this  
15 study is not supported by any grant; however, it may be supported by one or more grants from the  
16 Affiliated Hospital of Inner Mongolia Medical University or the Chinese government in future. The  
17 funders will not be involved in study design, sample collection, and data analyses.  
18  
19  
20  
21  
22  
23  
24  
25  
26

### 27 **Subject enrollment and specimen collection**

28  
29 Subjects who will be admitted to our hospital for an evaluation of the etiology of the pleural  
30 effusion will be eligible for enrollment. The presence of PE will be evaluated first by clinical  
31 examination and then further confirmed by chest imaging such as CT scan or ultrasound. The  
32 exclusion criteria are: (i) age less than 18 years; (ii) with a known diagnosis of a disease that could  
33 cause PE during the last three months; (iii) pregnancy; (iv) refused to sign informed consent; (v)  
34 with comorbidities that can prevent pleural fluid collection; (vi) subject dies during hospitalization  
35 without collection of pleural fluid and serum specimens; (vii) death of a subject during hospital stay  
36 before the final diagnosis; (viii) patients admitted without PE but developed PE after admission.  
37  
38  
39  
40  
41  
42  
43

44  
45 Pleural fluid specimen collection will be initiated after obtaining informed consent by the  
46 patient. Approximately 5-10 milliliters of pleural fluid specimen will be collected in a tube that does  
47 not contain any anticoagulant. The specimen will be sent to laboratory within 2 hours and  
48 centrifuged at 1200g for 10 minutes. The supernatants of the specimen will then be transferred to  
49 10 Eppendorf tubes (550 µl tube) and immediately frozen at -80°C for later use. A serum sample  
50 will be collected from the same patient within 24 hours before or after the pleural fluid collection to  
51 be frozen at -80 °C if available. A case report form will be used to record demographic and clinical  
52 details of the subjects, such as age, sex, side of PE (left-, right- or two-sided effusion), smoking  
53 history, conventional laboratory tests and microbiological findings.  
54  
55  
56  
57  
58  
59  
60



All subjects will be enrolled by a pulmonologist (L Yan). The subjects will be not consecutively enrolled because they may: (i) refuse to sign the informed consent; (ii) be admitted at weekend when Dr. Yan is not on duty; (iii) not be admitted to the Department of Respiratory and Critical Care Medicine of our institution.

The laboratory technician who determines the concentration of investigated markers will be blinded to clinical presentations of the subjects.

### Sample size estimation

As this is not a hypothesis-driven research and no new target disease or marker is proposed, we did not estimate the sample size before subjects' enrollment. The study execute time will last from September 2018 to July 2021. It is estimated that 200 to 300 subjects will be enrolled.

### Final diagnosis

This is an observational study that will not affect the further management of the enrolled subjects. The clinicians will decide the further diagnostic, treatment and management independent of this study. The etiologies of PE are diverse and the diagnostic criteria for the major diseases are listed in **Table 1**. The final diagnosis will be made by two researchers independently (L Yan and ZD Hu) and the results of investigated markers will not be known by them when making diagnosis.

**Table 1** Diagnostic criteria for major diseases related to PE

Etiology	Diagnostic criteria
Tuberculous	Identification of <i>Mycobacterium tuberculosis</i> in the sputum, pleural fluid, or pleural biopsy specimens [20], either by microscopy or cultures. In some cases with adequate clinical context, the diagnosis can be made with presence of granuloma in the parietal pleura, good response to anti-tuberculosis treatment, elevated level of pleural fluid adenosine deaminase or positive nucleic acid amplification tests (NAATs) [20–22].

Congestive heart failure	Typical clinical picture of CHF including the Framingham score, medical history and physical examination, the response to diuretic therapy, typical CHF features on chest X-ray, the echocardiographic evidence of left ventricular systolic dysfunction [15,23–25].
Malignant diseases	Identification of cancer cells in pleural fluid, sputum or bronchoalveolar lavage fluid by cytological examination, ultrasound or thoracoscopy-guided pleural biopsy [5,24].
Parapneumonic effusion	Typical clinical and radiological evidences of pneumonia, or a positive bacterial culture from pleural fluid, or good response to antibiotic therapy [5,24].
Pulmonary embolism	Computed tomographic pulmonary angiography (CTPA) [26].

Given that approximately 30% of PEs have more than one etiology and the most common secondary cause is CHF [27,28]. Therefore, all patients will be evaluated for concomitant presence of CHF. For some subjects, the differential diagnosis can change during their admission only the diagnosis at the time of specimen collection will be used. We also realize that a confirmed diagnosis is not possible in all cases with PE at the time of discharge. This can be due to the fact that some subjects might refuse to receive further diagnostic invasive approaches such as thoracoscopy. The number of these subjects will be recorded and reported. The patients without final diagnosis will be excluded from the final analysis or will be considered as control in the data analysis.

#### **Markers will be investigated in SIMPLE study**

In addition to routinely measured markers (e.g. ADA, NT-proBNP), several novel markers will be studied (e.g. soluble Fas ligand, presepsin and pentraxin-3 and interleukin 27). The serum and fluid markers intended to be investigated are listed in Table 2. It should be noted that the decision of whether or not to investigate these markers is greatly determined by the prevalence of target disease as well as statistical power. Novel markers which are not listed in Table 2 may also be studied if they showed high accuracy in identifying the etiologies of PE. In addition, the accuracy of Light criteria in differentiating exudate from transudate will also be studied.

**Table 2** Markers will be investigated in SIMPLE study

Target disease	Markers
Congestive heart failure	Mid-regional pro-atrial natriuretic peptide (MR-proANP)
Tuberculous pleurisy	Soluble Fas ligand; Interleukin 27 (IL-27); C-X- C motif chemokine receptor 3 (CXCR3) ligands
Malignant diseases	Soluble B7-H4; Human epididymis 4 (HE4); Cancer ratio; Dickkopf-1 (DDK1)
Parapneumonic effusion	Presepsin; Pentraxin-3

### Patient and public involvement

**Figure 1** is a flowchart depicting the study procedure. Subjects who will meet the inclusion and exclusion criteria will be invited to participate in this study. An informed consent will be signed before their participation. All subjects will not be involved in the recruitment and conduct of the study.

Routine serum and pleural fluid analysis will be ordered for these subjects. Pleural fluid specimens will be obtained for routine laboratory analysis, including cell count and differentiation, tumor markers, biochemistry, bacterial culture, Gram staining, cytology and nucleic acid amplification tests (NAAT). These laboratory tests will be ordered by the attending clinicians independent of this study. Approximately 5-10 milliliters of pleural fluid specimen will be collected simultaneously for research aims. All fluid and serum specimens will be collected at the time of admission before final diagnosis. The time period between the pleural fluid specimen collection and final diagnosis will be usually within one weeks, except for some subjects that need follow-up and therapy response to make diagnosis. Imaging (CT, MRI, CTPA), thoracoscopy and bronchoscopy will be ordered if necessary. The results of markers will be disseminated to the subjects via email or telephone upon request after the conclusion of the study.

### Dissemination and ethics

The results of SIMPLE will be submitted to international scientific peer-reviewed journals or conferences in laboratory medicine or respiratory medicine, thoracic diseases. This study has been approved by the Ethic Committee of the Affiliated Hospital of Inner Mongolia Medical University (NO: 2018011).

## Patient and public involvement statement

All subjects in SIMPLE study will not directly involved in the study design, recruitment and study conduction. There is no public involvement.

## Statistical analysis

Normal distribution of continuous data will be tested by Kolmogorov-Smirnov test. For the data with normal distribution, independent t-test or one-way ANOVA will be used for comparison; Otherwise, Mann-Whitney or Kruskal-Wallis tests will be used. Chi-square test will be used to compare categorized data. Receiver operating characteristics (ROC) curve analysis will be used to evaluate the diagnostic accuracy of the investigated markers. Area under ROC curve (AUC) will be used to estimate the overall diagnostic accuracy of a markers. AUCs of markers will be compared by the approach proposed by DeLong et al [29]. The optimal threshold will be determined with the method proposed by Pepe et al. [30] or maximum Youden index. When evaluating the diagnostic accuracy of a marker for a given disease, the subjects with this disease will be categorized into a disease group, regardless of whether other etiologies co-occur. Multivariable logistic regression model, net reclassification index (NRI) and integrated discriminatory index (IDI) will be used to evaluate whether a given marker provides added diagnostic information [31,32] beyond conventional diagnostic tools and clinical details (e.g. side information, age, sex, smoking history). Decision tree approach and decision curve analysis (DCA) [33] will be created to evaluate the preferred diagnostic strategy. All analyses will be performed with SPSS 18.0 (IBM Corporation, Chicago, United States), Sigmaplot 12.0 (Systat Software, Inc., San Jose, CA), Graphpad Prism 6.0 (GraphPad Software, La Jolla, CA) and R (<http://www.r-project.org>).

## Discussion

Multiple new diagnostic markers have been identified in the evaluation of PE with the advancement in omics approach and basic research. Therefore, it is valuable to evaluate the diagnostic accuracy of these markers rigorously. Although several studies have been performed on this topic [12,34,35], the result of these studies need to be validated. This is because that the diagnostic accuracy of a given marker may be affected by the disease spectrum of a study cohort

1  
2  
3  
4 [36]. Besides, majority of previous published studies evaluated only the diagnostic accuracy of  
5 single marker, and did not compare it with other promising markers. Furthermore, whether multi-  
6 marker strategy can improve the diagnostic accuracy remains largely unknown.  
7  
8

9  
10 Compared with previous studies, SIMPLE study has some strength. First, this is a registered,  
11 prospective, double-blind study. Therefore, the results of this study are more reliable. Second,  
12 majority of the previous studies did not consider the subjects with multiple etiologies of PE and this  
13 issue will be considered by SIMPLE study. Third, only limited studies have investigated whether a  
14 novel marker could provide added diagnostic information beyond traditional markers. In SIMPLE  
15 study, we will investigate this issue with IDI and NRI, although they have some shortcomings [37–  
16 40].  
17  
18  
19  
20  
21  
22

23 Multiple potential serum and fluid markers will be investigated in the SIMPLE study. Previous  
24 studies have indicated that presepsin is a useful diagnostic marker for bacterial infection [41,42];  
25 nevertheless, it remains unknown whether presepsin in serum or pleural fluid is useful for the  
26 diagnosis of parapneumonic effusion. Serum mid-regional pro-atrial natriuretic peptide (MR-  
27 proANP) has been reported to have high diagnostic accuracy for CHF [43]. However, only one  
28 study has investigated the diagnostic accuracy of MR-proANP in PE caused by CHF [23], and the  
29 results of this study need to be validated. In addition, some novel markers will also be studied, such  
30 as soluble Fas ligand [44] and interleukin 27 [12] for tuberculous pleurisy, soluble B7-H4 [45] and  
31 human epididymis 4 (HE4) [46] for malignant effusion. The results of SIMPLE study will be  
32 reported in accordance with the Standards for Reporting of Diagnostic Accuracy Studies (STARD)  
33 guideline [47]. For researches with multivariable prediction model, the report will comply with  
34 Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis  
35 (TRIPOD) statement [48].  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

48 SIMPLE study has some limitations. First, this is a single center study and representativeness  
49 of the study cohort is a limitation. Second, because it is not ethical to let all subjects receiving all  
50 diagnostic tools once a diagnosis has been made, partial verification bias can not be avoided. Indeed,  
51 establishing one diagnosis does exclude other etiologies. Third, the prognostic value of markers will  
52 not be evaluated in this study.  
53  
54  
55  
56  
57

58 Taken together, SIMPLE study is a prospective, double-blind diagnostic study aims to  
59 investigate the diagnostic accuracy of serum and pleural fluid markers. Although it has some  
60

1  
2  
3  
4 limitations, we believe that this study will provide a new insight into the PE etiological field.  
5  
6

#### 7 **Authors' contributions**

8  
9 Z.D. Hu conceived and designed the study; L Zhang, P.H. Ouyang and P Li provided administrative  
10 support; L Zhang, P.H. Ouyang, P Li, L Yan and Y.Q. Han drafted the manuscript. Z.D. Hu critically  
11 revised the manuscript; all authors approved the final version of the manuscript.  
12  
13  
14

#### 15 **Competing interests**

16  
17 None declared.  
18

#### 19 **Acknowledgements**

20  
21 We thank the clinicians in the Department of Respiratory and Critical Care Medicine and  
22 technicians in the Department of Laboratory Medicine for their support. We thank Dr. Hemant  
23 Goyal MD FACP from Mercer University School of Medicine for manuscript editing.  
24  
25  
26  
27  
28

29 **Funding:** None at current stage.  
30  
31  
32

#### 33 **References**

- 34  
35 1 Porcel JM, Esquerda A, Vives M, *et al.* Etiology of pleural effusions: analysis of more than  
36 3,000 consecutive thoracenteses. *Arch Bronconeumol* 2014;**50**:161–5.  
37  
38 2 Wang XJ, Yang Y, Wang Z, *et al.* Efficacy and Safety of Diagnostic Thoracoscopy in  
39 Undiagnosed Pleural Effusions. *Respiration* 2015;**90**:251–5.  
40  
41 3 Light RW, Macgregor MI, Luchsinger PC, *et al.* Pleural effusions: the diagnostic separation of  
42 transudates and exudates. *Ann Intern Med* 1972;**77**:507–  
43 13.<http://www.ncbi.nlm.nih.gov/pubmed/4642731> (accessed 16 Apr 2018).  
44  
45 4 Zhou Q, Ye ZJ, Su Y, *et al.* Diagnostic value of N-terminal pro-brain natriuretic peptide for  
46 pleural effusion due to heart failure: a meta-analysis. *Heart* 2010;**96**:1207–11.  
47  
48 5 Porcel JM, Azzopardi M, Koegelenberg CF, *et al.* The diagnosis of pleural effusions. *Expert*  
49 *Rev Respir Med* 2015;**9**:801–15.  
50  
51 6 Beaudoin S, Gonzalez A V. Evaluation of the patient with pleural effusion. *Can Med Assoc J*  
52 2018;**190**:E291–5.  
53  
54 7 Assawasaksakul T, Boonsarngsuk V, Incharoen P. A comparative study of conventional  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4 cytology and cell block method in the diagnosis of pleural effusion. *J Thorac Dis* 2017;**9**:3161–  
5  
6 7.
- 7  
8 Conde MB, Loivos AC, Rezende VM, *et al.* Yield of sputum induction in the diagnosis of  
9  
10 pleural tuberculosis. *Am J Respir Crit Care Med* 2003;**167**:723–5.
- 11  
12 Valdés L, Alvarez D, San José E, *et al.* Tuberculous pleurisy: a study of 254 patients. *Arch*  
13  
14 *Intern Med* 1998;**158**:2017–21. <http://www.ncbi.nlm.nih.gov/pubmed/9778201> (accessed 4 Oct  
15  
16 2018).
- 17  
18 Shivakumarswamy U, Karigowdar M, Arakeri S, *et al.* Diagnostic utility of the cell block  
19  
20 method versus the conventional smear study in pleural fluid cytology. *J Cytol* 2012;**29**:11.
- 21  
22 Kastelik JA. Management of Malignant Pleural Effusion. *Lung* 2013;**191**:165–75.
- 23  
24 Wang W, Zhou Q, Zhai K, *et al.* Diagnostic accuracy of interleukin 27 for tuberculous pleural  
25  
26 effusion: Two prospective studies and one meta-analysis. *Thorax* 2018;**73**:240–7.
- 27  
28 Jiang J, Shi HZ, Liang QL, *et al.* Diagnostic value of interferon-gamma in tuberculous pleurisy:  
29  
30 a metaanalysis. *Chest* 2007;**131**:1133–41.
- 31  
32 Liang QL, Shi HZ, Wang K, *et al.* Diagnostic accuracy of adenosine deaminase in tuberculous  
33  
34 pleurisy: A meta-analysis. *Respir Med* 2008;**102**:744–54.
- 35  
36 Han ZJ, Wu XD, Cheng JJ, *et al.* Diagnostic accuracy of natriuretic peptides for heart failure in  
37  
38 patients with pleural effusion: A systematic review and updated meta-Analysis. *PLoS One*  
39  
40 2015;**10**:e0134376.
- 41  
42 Hu ZD, Liu XF, Liu XC, *et al.* Diagnostic accuracy of osteopontin for malignant pleural  
43  
44 mesothelioma: a systematic review and meta-analysis. *Clin Chim Acta* 2014;**433**:44–8.
- 45  
46 Liang QL, Shi HZ, Qin XJ, *et al.* Diagnostic accuracy of tumour markers for malignant pleural  
47  
48 effusion: a meta-analysis. *Thorax* 2008;**63**:35–41.
- 49  
50 He C, Wang B, Li D, *et al.* Performance of procalcitonin in diagnosing parapneumonic pleural  
51  
52 effusions. *Medicine (Baltimore)* 2017;**96**:e7829.
- 53  
54 Zou MX, Zhou RR, Wu WJ, *et al.* The use of pleural fluid procalcitonin and C-reactive protein  
55  
56 in the diagnosis of parapneumonic pleural effusions: a systemic review and meta-analysis. *Am*  
57  
58 *J Emerg Med* 2012;**30**:1907–14.
- 59  
60 Zhai K, Lu Y, Shi HZ. Tuberculous pleural effusion. *J Thorac Dis* 2016;**8**:E486–94.
- Trajman A, Pai M, Dheda K, *et al.* Novel tests for diagnosing tuberculous pleural effusion:



- 1  
2  
3  
4 what works and what does not? *Eur Respir J* 2008;**31**:1098–106.
- 5  
6 22 Porcel JM. Advances in the diagnosis of tuberculous pleuritis. *Ann Transl Med* 2016;**4**:282.
- 7  
8 23 Porcel JM, Bielsa S, Morales-Rull JL, *et al.* Comparison of pleural N-terminal pro-B-type  
9 natriuretic peptide, midregion pro-atrial natriuretic peptide and mid-region pro-adrenomedullin  
10 for the diagnosis of pleural effusions associated with cardiac failure. *Respirology* 2013;**18**:540–  
11 5.  
12  
13  
14
- 15 24 Kolditz M, Halank M, Schiemanck CS, *et al.* High diagnostic accuracy of NT-proBNP for  
16 cardiac origin of pleural effusions. *Eur Respir J* 2006;**28**:144–50.  
17  
18
- 19 25 Liao H, Na MJ, Dikensoy O, *et al.* Diagnostic value of pleural fluid N-terminal pro-brain  
20 natriuretic peptide levels in patients with cardiovascular diseases. *Respirology* 2008;**13**:53–7.  
21  
22
- 23 26 Konstantinides S V., Torbicki A, Agnelli G, *et al.* 2014 ESC Guidelines on the diagnosis and  
24 management of acute pulmonary embolism. *Eur. Heart J.* 2014;**35**:3033–80.  
25  
26
- 27 27 Bintlcliffe OJ, Hooper CE, Rider IJ, *et al.* Unilateral pleural effusions with more than one  
28 apparent etiology: A prospective observational study. *Ann Am Thorac Soc* 2016;**13**:1050–6.  
29  
30
- 31 28 Walker S, Maskell N. Identification and management of pleural effusions of multiple  
32 aetiologies. *Curr Opin Pulm Med* 2017;**23**:339–45.  
33  
34
- 35 29 DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more  
36 correlated receiver operating characteristic curves: a nonparametric approach. *Biometrics*  
37 1988;**44**:837–45.<http://www.ncbi.nlm.nih.gov/pubmed/3203132>  
38  
39
- 40 30 Pepe MS, Janes H, Li CI, *et al.* Early-Phase Studies of Biomarkers: What Target Sensitivity  
41 and Specificity Values Might Confer Clinical Utility? *Clin Chem* 2016;**62**:737–42.  
42  
43
- 44 31 Moons KG, de Groot JA, Linnet K, *et al.* Quantifying the added value of a diagnostic test or  
45 marker. *Clin Chem* 2012;**58**:1408–17.  
46  
47
- 48 32 Pencina MJ, D'Agostino Sr. RB, D'Agostino Jr. RB, *et al.* Evaluating the added predictive  
49 ability of a new marker: from area under the ROC curve to reclassification and beyond. *Stat*  
50 *Med* 2008;**27**:112–57.  
51  
52
- 53 33 Vickers AJ, Elkin EB. Decision Curve Analysis: A Novel Method for Evaluating Prediction  
54 Models. *Med Decis Mak* 2006;**26**:565–74.  
55  
56
- 57 34 Chung W, Jung Y, Lee K, *et al.* CXCR3 ligands in pleural fluid as markers for the diagnosis of  
58 tuberculous pleural effusion. *Int J Tuberc Lung Dis* 2017;**21**:1300–6.  
59  
60



- 1  
2  
3  
4 35 Pass HI, Levin SM, Harbut MR, *et al.* Fibulin-3 as a blood and effusion biomarker for pleural  
5 mesothelioma. *N Engl J Med* 2012;**367**:1417–27.
- 6  
7  
8 36 Linnet K, Bossuyt PM, Moons KG, *et al.* Quantifying the Accuracy of a Diagnostic Test or  
9 Marker. *Clin Chem* 2012;**58**:1292–301.
- 10  
11  
12 37 Pepe MS, Fan J, Feng Z, *et al.* The Net Reclassification Index (NRI): a Misleading Measure of  
13 Prediction Improvement Even with Independent Test Data Sets. *Stat Biosci* 2015;**7**:282–95.
- 14  
15  
16 38 Gerds TA, Hilden J. Calibration of models is not sufficient to justify NRI. *Stat Med*  
17 2014;**33**:3419–20.
- 18  
19  
20 39 Hilden J. Commentary: On NRI, IDI, and “good-looking” statistics with nothing  
21 underneath. *Epidemiology* 2014;**25**:265–7.
- 22  
23  
24 40 Hilden J, Gerds TA. A note on the evaluation of novel biomarkers: do not rely on integrated  
25 discrimination improvement and net reclassification index. *Stat Med* 2014;**33**:3405–14.
- 26  
27  
28 41 Wu J, Hu L, Zhang G, *et al.* Accuracy of Procalcitonin in Sepsis Diagnosis: A Systematic Review  
29 and Meta-Analysis. *PLoS One* 2015;**10**:e0133057.
- 30  
31  
32 42 Zhang J, Hu ZD, Song J, *et al.* Diagnostic Value of Procalcitonin for Sepsis: A Systematic Review  
33 and Meta-Analysis. *Med* 2015;**94**:e2158.
- 34  
35  
36 43 Hu Z, Han Z, Huang Y, *et al.* Diagnostic power of the mid-regional pro-atrial natriuretic  
37 peptide for heart failure patients with dyspnea: A meta-analysis. *Clin Biochem* 2012;**45**:1634–  
38 9.
- 39  
40  
41 44 Wu SH, Li CT, Lin CH, *et al.* Soluble Fas ligand is another good diagnostic marker for  
42 tuberculous pleurisy. *Diagn Microbiol Infect Dis* 2010;**68**:395–400.
- 43  
44  
45 45 Xu C, Qian L, Yu L, *et al.* Evaluation of serum and pleural levels of soluble B7-H4 in lung  
46 cancer patients with pleural effusion. *Biomarkers* 2015;**20**:271–4.
- 47  
48  
49 46 Elsammak MY, Attia A, Hassan HA, *et al.* Evaluation of pleural fluid human epididymis 4  
50 (HE4) as a marker of malignant pleural effusion. *Tumour Biol* 2012;**33**:1701–7.
- 51  
52  
53 47 Bossuyt PM, Reitsma JB, Bruns DE, *et al.* STARD 2015: An Updated List of Essential Items  
54 for Reporting Diagnostic Accuracy Studies. *Clin Chem* 2015;**61**:1446–52.
- 55  
56  
57 48 Collins GS, Reitsma JB, Altman DG, *et al.* Transparent reporting of a multivariable prediction  
58 model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. *BMJ*  
59 2015;**350**:g7594–g7594.
- 60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Figure legend**

**Figure 1.** Flowchart of study procedure.

For peer review only




Figure 1. Flowchart of study procedure.

64x90mm (300 x 300 DPI)